The Oncologist ® Academia–Pharma Intersect: Gastrointestinal Cancer Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery SABINE TEJPAR,a MONICA BERTAGNOLLI,b FRED BOSMAN,c HEINZ-JOSEPH LENZ,d LEVI GARRAWAY,e FREDERIC WALDMAN,f ROBERT WARREN,g ANDREA BILD,h DENISE COLLINS-BRENNAN,b HEJIN HAHN,i D. PAUL HARKIN,j RICHARD KENNEDY,j MOHAMMAD ILYAS,k HANS MORREAU,l VITALI PROUTSKI,j CHARLES SWANTON,m IAN TOMLINSON,n MAURO DELORENZI,o ROBERTO FIOCCA,p ERIC VAN CUTSEM,a ARNAUD ROTHq aDigestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; bDepartment of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts, USA; cDepartment of Pathology, Lausanne University, Lausanne, Switzerland; dKeck School of Medicine, University of Southern California, Los Angeles, California, USA; eMedical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; fDepartment of Urology and gDepartment of Surgery, University of California, San Francisco, CA, USA; hDepartment of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah, USA; iDepartment of Pathology, Virginia Mason Medical Center, Seattle, Washington, USA; jAlmac Diagnostics, Cambridge, Massachusetts, USA; kSchool of Molecular Medical Sciences, University of Nottingham, Nottingham, UK; lDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands; mCancer Research UK, London Research Institute, Royal Marsden Hospital, London, UK; nMolecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London, UK; oSwiss Institute of Bioinformatics, Lausanne, Switzerland; pDepartment of Surgical and Morphological Science, University of Genova, Genova, Italy; qOncosurgery, University Hospital of Geneva, Geneva, Switzerland Disclosures: Sabine Tejpar: None; Monica Bertagnolli: Honoraria: Pfizer; Fred Bosman: Research funding/contracted research: Pfizer; Heinz-Joseph Lenz: Intellectual property rights/inventor/patent holder: Abraxis; Research funding/contracted research: Genentech, ImClone, Roche, BMS, Merck, Pfizer; Ownership interest: Responsegenetics; Levi Garraway: Consultant/advisory role: Novartis; Research funding/contracted research: Novartis; Frederic Waldman: None; Robert Warren: Research funding/ contracted research: NCCN; Andrea Bild: None; Denise Collins-Brennan: None; Hejin Hahn: None; D. Paul Harkin: Employment/leadership position: Almac Diagnostics; Ownership interest: Almac Diagnostics; Richard Kennedy: Employment/ leadership position: Almac Diagnostics; Mohammad Ilyas: None; Hans Morreau: None; Vitali Proutski: None; Charles Swanton: None; Ian Tomlinson: None; Mauro Delorenzi: None; Roberto Fiocca: Research funding/contracted research: Pfizer; Eric Van Cutsem: Research funding/contracted research: Pfizer; Arnaud Roth: Honoraria: Pfizer. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers. ABSTRACT The number of agents that are potentially effective in the adjuvant treatment of locally advanced resectable colon cancer is increasing. Consequently, it is important to ascertain which subgroups of patients will benefit Correspondence: Sabine Tejpar, M.D., Ph.D., Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, B - 3000 Leu- ven, Belgium. Telephone: 32-16-344218; Fax: 32-16-344419; e-mail: sabine.tejpar@uz.kuleuven.ac.be Received September 28, 2009; accepted for publication February 22, 2010; first published online in The Oncologist Express on March 29, 2010; available online without subscription through the open access option. ©AlphaMed Press 1083-7159/2010/$30.00/0 doi: 10.1634/theoncologist.2009-0233 The Oncologist 2010;15:390 – 404 www.TheOncologist.com